Dr. Julien Meissonnier, Pharmaceutical Softgel Europe, Catalent looks at lipid-based formulations to increase the bioavailability of poorly soluble drugs.
Poor solubility remains an ongoing challenge in formulation development. The number of poorly soluble compounds is estimated to be 40% of molecules on the market, however, more than 70% of drugs in development are classified as poorly soluble.1,2